Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Tumor-initiating cells escape tumor immunity via CCL8 from tumor-associated macrophages in mice
Shuang Chen, Chensong Huang, Kang Li, Maosheng Cheng, Caihua Zhang, Jianqi Xiong, Guoli Tian, Ruoxing Zhou, Rongsong Ling, Xiaochen Wang, Gan Xiong, Zhihui Zhang, Jieyi Ma, Yan Zhu, Bin Zhou, Liang Peng, Zhenwei Peng, Heping Li, Demeng Chen
Shuang Chen, Chensong Huang, Kang Li, Maosheng Cheng, Caihua Zhang, Jianqi Xiong, Guoli Tian, Ruoxing Zhou, Rongsong Ling, Xiaochen Wang, Gan Xiong, Zhihui Zhang, Jieyi Ma, Yan Zhu, Bin Zhou, Liang Peng, Zhenwei Peng, Heping Li, Demeng Chen
View: Text | PDF
Research Article Oncology

Tumor-initiating cells escape tumor immunity via CCL8 from tumor-associated macrophages in mice

  • Text
  • PDF
Abstract

Tumor-initiating cells (TICs) play a key role in cancer progression and immune escape. However, how TICs evade immune elimination remains poorly characterized. Combining single-cell RNA-Seq (scRNA-Seq), dual-recombinase–based lineage tracing, and other approaches, we identified a WNT-activated subpopulation of malignant cells that act as TICs in vivo. We found intensive reciprocal interactions between TICs and immune-regulatory tumor-associated macrophages (Reg-TAMs) via growth arrest–specific 6/AXL receptor tyrosine kinase/MER proto-oncogene, tyrosine kinase (GAS6/AXL/MERTK) signaling pathways, which facilitated the immune escape of TICs. In this study, we used chemical inhibitors and Axl/Mertk conditional double-KO (cDKO) mice to demonstrate that inhibiting the interaction between TIC-derived GAS6 and AXL/MERTK in Reg-TAMs reactivated antitumor immune responses. We identified CCL8 as a critical mediator of the GAS6/AXL/MERTK pathway, primarily by inhibiting Treg infiltration into the tumor. Furthermore, the AXL/MERTK signaling blockade sensitized tumor cells to anti–programmed cell death 1 (anti–PD-1) treatment. Thus, we elucidated a detailed mechanism by which TICs evade tumor immunity, providing insights into strategies to eradicate TICs that escape conventional immunotherapy.

Authors

Shuang Chen, Chensong Huang, Kang Li, Maosheng Cheng, Caihua Zhang, Jianqi Xiong, Guoli Tian, Ruoxing Zhou, Rongsong Ling, Xiaochen Wang, Gan Xiong, Zhihui Zhang, Jieyi Ma, Yan Zhu, Bin Zhou, Liang Peng, Zhenwei Peng, Heping Li, Demeng Chen

×

Figure 2

WNT-activated cells constitute a TIC population in mouse ICC.

Options: View larger image (or click on image) Download as PowerPoint
WNT-activated cells constitute a TIC population in mouse ICC.
(A) UMAP p...
(A) UMAP plot showing 4 epithelial cell subclusters. (B) RNA velocity–inferred developmental trajectory of epithelial cells. (C) UMAP plots showing the distribution of CytoTRACE scores for epithelial cells. Higher scores indicate higher stemness. (D) Monocle pseudotime trajectory showing cell differentiation of 4 epithelial cell subclusters. (E) Heatmap of GSVA-enriched pathways in epithelial cell clusters. (F) Schematic of lineage tracing. (G) Experimental strategies for lineage tracing of AXIN2+KRT19+ epithelial cells in ICC mice. d0, day 0. (H) Violin plots showing Sox4 and Klf6 expression among epithelial cell subclusters. (I and L) Representative fluorescence images of SOX4 (green) and KLF6 (green) staining and Tom+ cells (red) in ICC tumors. Nuclei are stained with DAPI (blue). Scale bar: 50 μm. (J, K, M, and N) Statistical analysis of SOX4+ and KLF6+ expression in Tom+/– mouse ICC cells. (O and Q) Representative fluorescence images showing EdU+ (green), SCP2+ (green), ATP6V1F+ (green), and Tom+ (red) cells in ICC after tamoxifen treatment. Nuclei are stained with DAPI (blue). Scale bars: 50 μm. (P and R) Comparison of the percentage of Tom+EdU+, Tom+SCP2+, and Tom+ATP6V1F+ cells in ICC induced for 3 days, with results shown at 7, 14, and 21 days. (S) Flow cytometry plots of EpCAM+Tom+ tumor cells that were isolated and from ICC tissues and sorted. (T and U) Tumor formation frequency of EpCAM+Tom+ and EpCAM+Tom– ICC cells in vivo (T), analyzed by the single-hit model likelihood ratio test (U). Data represent the mean ± SD J, K, P and R). P values were calculated by 2-tailed, unpaired Student’s t test (H, J, K, M, and N) and 1-way ANOVA with Tukey’s multiple-comparison test (P and R).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts